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Non-small cell lung cancer (NSCLC) that has a T-stagebetween T1 and T3 and that has spread to the hipsilateral
mediastinal lymphnodes is defined as stage IIIA-N2. Patients
diagnosed at this stage represent approximately 20% of all
patients with lung cancer. However, within the same stage,
patients’ outcome and management highly depends on the
extension of mediastinal involvement and on other factors
that are not actually included in the currently used interna-
tional staging system. In fact, in technically resectable N2
disease, minimal or clinical involvement has different sur-
vival impact,1 whereas in the so-called N2-bulky disease
(multistation, fixed, or extracapsular spread), the total volume
of primary tumor and metastasis burden have an inverse
correlation with survival.2 Moreover, if N2 bulky disease is
treated together with stage IIIB NSCLC, with a combination
of chemo- and radiotherapy, the current management of
clinical, technically resectable, N2 disease is still debated.
However, if N2 bulky disease in patients with stage IIIB
NSCLC is treated together with a combination of chemo- and
radiotherapy, the current management of clinical, technically
resectable, N2 disease is still debated.
In these two groups of patients, induction chemother-
apy has several endpoints. Its aim is to reduce tumor volume,
reach a complete response at the mediastinal level, and thus
allow a curative surgical resection. Moreover, the goal of
systemic treatment before surgery is to control distant micro-
metastases and thus improve patients’ overall survival. How-
ever, evidence of the benefit of this approach for patients who
could receive surgery as primary intervention is not conclu-
sive for several reasons: proper staging of the mediastinum
with invasive intervention, such as mediastinoscopy or trans-
bronchial biopsy, at diagnosis and eventually for the assess-
ment of response after induction treatment; the eventual role
of noninvasive procedures, such as positron emission tomog-
raphy (PET) for the same purpose; the role of adjuvant
radiotherapy, which in early stages of disease is detrimental,3
but whose role in stage IIIA is still controversial; finally, the
stronger evidence that postoperative chemotherapy has
gained over the last years and its demonstrated improvement
in survival compared with surgery alone in very large phase
III trials of patients with radically resected tumors.4 However,
preoperative chemotherapy with cisplatin and third-genera-
tion drug combinations has been demonstrated to be active
and extremely well tolerated. The response rate ranges be-
tween 50% and 70%, much higher than that in advanced
disease, with a complete response rate of 5% to 15%. Tox-
icity is low and manageable, treatment compliance is high
because of the lower burden of tumor-related symptoms, and
surgery-related mortality after neoadjuvant chemotherapy is
not increased.
RANDOMIZED TRIALS OF INDUCTION
CHEMOTHERAPY
The role of neoadjuvant chemotherapy versus surgery
alone was explored in the early 1990s in two phase III trials
that were prematurely stopped because of the striking im-
provement in survival for the study arm versus the control
arm (approximately 20 vs 10 months, respectively).5,6 Up-
dated reports of these trials demonstrated how the benefit of
this approach could be long-lasting7,8 (Table 1).
Unfortunately, these results were not confirmed by two
other trials.9,10 The major limitations of these studies were the
small sample size (an average of 30 patients per study arm in
three trials, whereas one trial enrolled 170 patients per arm10),
an often non-rigorous pretreatment surgical assessment of
mediastinal spread, a mixture of patients at different stages
(from IB to IIIA), the non-standardized use of postoperative
chemo- and radiotherapy, and the use of second-generation
platinum-based combination treatments.
Despite the heterogeneity of these studies, in a recent
meta-analysis,11 the advantage of neoadjuvant chemotherapy
followed by surgical resection versus surgery alone for pa-
tients with resectable disease has been clearly defined, even
in the subset of patients with N2 disease (HR 0.66 [95% CI,
0.48–0.93]).
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NEW INDUCTION REGIMENS:
PLATINUM-BASED DOUBLETS
AND TRIPLETS
With the advent of third-generation drugs, i.e. gemcit-
abine, vinorelbine, taxanes, the interest in induction chemo-
therapy has increased, and this has led to several phase II
trials with third-generation drugs combined with platinum.
The EORTC 08941 trial is a phase III study that
randomized patients with pN2 NSCLC to surgery or radio-
therapy after a partial response to induction chemotherapy.
Final results are awaited, but from this study, three separate
phase II trials reporting the results of induction chemotherapy
alone with cisplatin-gemcitabine,12 cisplatin-docetaxel,13 or
carboplatin-paclitaxel14 have already been published. Induc-
tion chemotherapy was well tolerated, and the response rate
was 40% to 70%. Among all patients randomized to the
surgery arm, radical resection was obtained in 49.7% of
cases, and pathological down-staging to N0 or N1 disease
was achieved in 40.9% of patients.15
Cisplatin combined with docetaxel or gemcitabine was
administered as induction chemotherapy to patients with N2
disease in two other studies.16,17 Again, although one of these
studies included only resectable-N2 disease,16 whereas our
trial also included selected non-N3 stage IIIB patients,17
response rates were similar (approximately 60%). The per-
centage of pathological clearance of mediastinal lymphnodes
was 60% in the first study, versus 20% in our study that also
enrolled non-resectable disease.
To improve the activity of induction chemotherapy in
patients with N2 disease, we added a third drug (paclitaxel) to
the combination of cisplatin and gemcitabine.18 All 49 pa-
tients enrolled in this phase II study had biopsy-proven
mediastinal disease; the response rate was 73.5%, and radical
surgery after induction chemotherapy was performed in 55%
of patients. In 35% of all patients (17 of 49), mediastinal
lymphnodes were found to be tumor-free at surgery. Median
survival time was 23 months. Moreover, the triplet was very
well tolerated, with grade 3 or 4 neutropenia recorded in 30%
of patients.
A Spanish trial19 assessed the activity of another triplet
with cisplatin, vinorelbine, and gemcitabine as induction
treatment in locally advanced disease. This regimen achieved
a response rate of 52% and median survival time of 12.5
months. Compared with the CGP combination, these results
seem disappointing. However, the patient population selected
in the Spanish trial had a worse prognosis compared with the
previous Italian trial (76% of patients with stage IIIB vs 0%
in the De Marinis et al.18 trial). This may have led to a lower
probability of down-staging after induction chemotherapy, to
a reduced possibility of performing radical surgery, and thus
to shorter overall survival. (Table 2).
PLATINUM-FREE INDUCTION COMBINATIONS
Another phase II trial has explored the activity of a
platinum-free combination of gemcitabine and vinorelbine as
induction treatment among 62 patients with resectable
NSCLC, including stage I-IIIA (N2).20 In the overall popu-
lation, the response rate was 37%, and of the 11 patients who
had N2 disease at initial staging and underwent surgery,
mediastinal lymphnodes were negative in only 2 patients.
Therefore, this combination indirectly shows less activity in
this setting than combinations that include platinum.
ROLE OF RADIOTHERAPY AS INDUCTION
COMBINATION TREATMENT
The role of radiotherapy in this setting has been ex-
plored in studies other than the EORTC 08941 trial. In a
phase II trial,21 patients with N2 disease (either resectable or
bulky) were non-randomly treated with platinum-based che-
TABLE 1. Phase III Randomized Trials of Neoadjuvant Chemotherapy Followed by Surgery versus Surgery Alone in Patients
with Resectable Non-small Cell Lung Cancer
Study Stage n Neoadjuvant Treatment
Pretreatment Surgical
Assessment of Mediastinal
Lymph-node Status Median Survival (mo) 3-year Survival (%)
Rosell et al.5,7 IIIAa 30b Mitomicin, ifosfamide,
cisplatin
Only in patients with cN2
disease
22 20
30b None 10 5
Roth et al.6,8 IIIAa 28b Etoposide, cyclophosphamide,
cisplatinc
Only in patients with cN2
disease
21 43
32b None 14 19
Nagai et al.9 IIIA-N2 31d Vindesine, cisplatin In all patients 17e 23
31d None 16e 26
Depierre et al.10 IB-IIIA 179 Mitomicin, ifosfamide,
cisplatinf
Optional 37e 51.6
176 None 26e 41.2
a 26% of patients with stage T3 N0-1 disease.
b Trials stopped prematurely for striking difference in survival noted at interim analysis.
c Of the responding patients, 81% received three further cycles of adjuvant chemotherapy.
d Trial stopped prematurely for excessively slow accrual.
e No statistically significant difference.
f Of responding patients, 84% received two further cycles of adjuvant chemotherapy.
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motherapy or chemoradiation as neoadjuvant therapy, fol-
lowed by surgical resection. If the percentage of R0-resection
and postoperative mortality after induction treatment was
similar in both groups (approximately 90% and 3%, respec-
tively), patients treated with induction chemoradiation had
higher pathological mediastinal down-staging (78% versus
61%). In an earlier phase III trial,22 73 patients with pN2
disease (again either bulky or resectable) were randomized to
radiotherapy or surgery after induction chemotherapy with a
second-generation cisplatin-based triplet. No differences in
survival were demonstrated between the two arms, and com-
plete surgical resection was achieved in 73% of patients
undergoing thoracotomy. Finally, the second interim analysis
of the most important phase III trial in this setting, designed
to better clarify the role of radiotherapy as induction or
definite treatment, was published recently.23 In this trial, after
an induction treatment with chemoradiation, 429 patients
with resectable pN2 disease were randomized to complete
chemoradiation until the full dose was reached or to surgical
resection. Further adjuvant/consolidation chemotherapy was
administered in both arms. The preliminary results show a
higher incidence of esophagitis for the full-dose chemoradia-
tion arm but a non-significant difference in survival between
the two arms (p  0.24).
CONCLUSIONS
In conclusion, the main problems in generalizing the
results of the recent phase II studies with neoadjuvant che-
motherapy are the different schedules and regimens used, the
mixture of resectable and non-resectable disease even within
the same group of patients with N2 disease, and, finally, the
overall non-outstanding rate of operability after induction
chemotherapy. In fact, although surgical resection in patients
with complete response at the mediastinal level is the optimal
treatment, the survival of patients whose mediastinum is still
positive after induction chemotherapy remains poor. In this
latter subset of patients, the role of surgery is still debated,
because similar results could be obtained by sequentially
adding full-dose radiotherapy to neoadjuvant chemotherapy.
However, phase III randomized trials have demonstrated a
survival advantage and higher local control rate by using
full-dose concomitant chemo-and radiotherapy versus se-
quential approaches, even in patients with N2 disease.24
Treating patients with resectable N2 disease with induction
chemotherapy without achieving a complete response in the
mediastinum (which is still the case in most patients), then
completing the treatment with sequential radiotherapy, could
be an under-treatment given the demonstrated survival ad-
vantage of adjuvant chemotherapy after surgery in resectable
disease and the better results of using concurrent versus
sequential chemoradiation in unresectable disease.
Open Questions
Finally, although neoadjuvant chemotherapy is consid-
ered a standard of care for patients with resectable disease in
the updated guidelines of the European Society of Medical
Oncology,25 several issues still remain to be assessed for the
proper management of stage IIIA-N2 NSCLC. Among other
factors, the optimal regimen to use as induction treatment has
not yet been established. Possible neoadjuvant strategies
could consist in induction chemotherapy alone to patients
with minimal mediastinal involvement, whereas treatment
with a more aggressive combination of chemo- and radio-
therapy could be more suitable for those patients with a
higher tumor burden. In this latter case, a fast and effective
re-evaluation would direct patients to surgical resection or
definite local treatment with the same induction schedule at
full doses. In the future, a phase III trial properly powered to
detect differences in survival should challenge preoperative
versus postoperative chemotherapy. A similar trial is ongo-
ing, (NATCH trial) but unfortunately its target is limited to
patients with stage I-IIIA(N1) disease.
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